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Chapter 5
Gene expression profiling 
in a rat model of flow-associated
 pulmonary hypertension: 
effects of pulmonary blood flow and 
prostacyclin treatment
Mirjam E. van Albada, Beatrijs Bartelds, Hans Wijnberg, 
Saffloer Mohaupt, Regien G. Schoemaker, Krista Kooi, 




Introduction: Pulmonary arterial hypertension is a disease with high morbidity and 
mortality. Increased pulmonary blood flow can trigger pulmonary arterial hyperten-
sion, but the pathophysiological mechanisms are unclear. We employed a rat model 
of flow-associated pulmonary arterial hypertension to explore the pathophysiologi-
cal mechanisms at molecular level and to test the effects of a commonly used treat-
ment: the prostacyclin analogue iloprost.
Methods: Male Wistar rats were injected with monocrotaline (60 mg/kg) followed 
by sham surgery or the creation of an abdominal aortocaval shunt one week later. 
Rats that were injected with saline and sham operated served as healthy controls. 
Part of the rats with the combination of monocrotaline and a shunt was treated with 
the prostacyclin analogue iloprost (72 µg/kg/day in osmotic minipumps). A semi-
randomized cross-over experiment was performed with lung mRNA microarray. 
Important results were verified by RT-PCR.
Results: Clustering of significantly regulated genes revealed expression profiles for 
each group. Monocrotaline-treated rate had increased mast cell proliferation, which 
was diminished by iloprost treatment. Increased pulmonary blood flow specifically 
led to increased expression of activating transcription factor 3 and early growth re-
sponse protein 1. Wnt-signaling was altered both by monocrotaline and by the in-
duction of increased pulmonary blood flow. Moreover, iloprost treatment increased 
several genes from the Wnt-signaling pathway. 
Conclusion: Monocrotaline and increased pulmonary blood flow each contribute 
to specific changes in pulmonary gene expression that could be of importance in 
the pathogenesis of pulmonary arterial hypertension. Treatment with iloprost partly 
reverses these changes. Interesting new pathobiological pathways emerged from this 
analysis. 
Chapter  5
Gene expression profiling in a rat m
odel of flow
-associated pulm
onary hypertension:  
effects of pulm
onary blood flow




Pulmonary arterial hypertension is a disease with high morbidity and mortality. It is 
caused by progressive pulmonary vascular obliteration and often occurs in patients 
with large cardiac left-to-right shunts 1. The pathological mechanism at a molecular 
level is still poorly understood. Interestingly, the presence of increased pulmonary 
blood flow appears to be a predisposing factor in a large number of patients 2. Treat-
ment with prostacyclin analogues is effective in diminishing disease severity 3-6. 
However, the mechanism behind this therapy is also poorly understood.
Several animal models for pulmonary arterial hypertension (PAH) have been devel-
oped. The monocrotaline rat model is a classical rat model for PAH associated with 
increased pulmonary pressures, but these animals do not develop advanced pulmo-
nary vascular lesions and this model lacks the component of increased pulmonary 
blood flow as is present in patients with congenital heart defects 7. Secondly, animal 
models using solely increased flow were explored. These models usually show in-
creased medial wall thickness of the pulmonary vessels without further associated 
remodeling 8-10. Finally, combination models with both an increase in pulmonary 
blood flow and in pressure were developed 11-14. 
In our laboratory, we employ a rat model using monocrotaline in combination with 
an abdominal aortacaval shunt. This rat model displays severely increased pulmo-
nary arterial pressures, advanced pulmonary vascular lesions and progressive right 
ventricular failure 14. We used this model to identify pathways that are important 
in the pathogenesis of flow-associated PAH and to test whether these pathways are 
involved in mediating the effects of iloprost treatment. For that purpose, we per-
formed a semi-randomized cross-over designed microarray experiment with mRNA 
isolated from total lung tissue. We verified the most important results histopatho-
logically and using RT-PCR.
Methods
We compared pulmonary gene expression levels in four animal groups using a 
cross-over designed microarray experiment. Rats that were administered monocro-
taline (MC) were compared to healthy controls (CON) and to rats that received 
both monocrotaline and an abdominal aortocaval shunt (MC + AV). Finally, iloprost 
treated MC+AV rats were compared to saline treated MC + AV rats. 
Animal model
Twenty-four male Wistar rats (Harlan, the Netherlands) weighing 250-300g were 
used. Animal care and experiments were conducted according to the Dutch Animal 
Experimental Act. The Erasmus University and the University of Groningen Animal 
Care and Use Committees approved the experimental protocols. 
Rats were randomly assigned to the four experimental groups: 1) control (CON; n 
82
= 6), 2) monocrotaline-treated rats (MC; n = 6; single dose of monocrotaline 60 
mg/kg sc, Sigma Chemical Co, St. Louis, MO, USA), 3) monocrotaline plus aortoca-
val shunt (MC + AV; n = 6; monocrotaline injection followed by the creation of an 
abdominal aortocaval shunt one week later 14, 4) MC + AV treated with the prostacy-
clin analogue iloprost (ILO; n = 6). Rats were weighed, daily watched for dyspnea, 
defined as the use of accessory respiratory muscles and/or gasping, and sacrificed 
when a 15% weight loss or debilitating dyspnea occurred. Matched rats in the other 
experimental groups were sacrificed simultaneously.
Treatment protocols
Osmotic minipumps (model 2004, Alzet, Palo Alto, CA, USA) with iloprost (72 
µg/kg/day; a generous gift of Schering, the Netherlands) were implanted subcu-
taneously in the same operative session as the creation of the abdominal aortocaval 
shunt. 
Hemodynamic measurements
The mean day of sacrifice was 36.5 ± 0.6 days after the administration of monocro-
taline. At the time of sacrifice, rats were anesthetized with pentobarbital (60 mg/kg 
intraperitoneally) and ventilated with room air. Pulmonary arterial pressures were 
measured with a technique described by Rabinovitch 15 that is routinely used in our 
laboratory 14. If pulmonary arterial pressure could not be obtained, right ventricular 
systolic pressure was recorded as being equal to systolic pulmonary arterial pressure. 
By introducing a catheter via the left carotid artery into the aorta, systemic arterial 
pressures as well as heart rate were measured.
RNA isolation and experimental design of the microarray  
experiment
RNA was isolated from total frozen lung tissue using a Qiagen RNeasy kit (Qiagen, 
Venlo, The Netherlands). A DNase treatment step (RNase free DNase, Qiagen) was 
included in the protocol. Integrity and concentration of RNA was controlled using 
the Agilent 2100 Bioanalyzer (Agilent, Palo Alto, CA, USA). The microarray experi-
ment was designed to meat the MIAME criteria for microarray data 16. To minimize 
biases due to biological variation of the individual rats, each sample for microarray 
analysis contained equal amounts of pooled RNA from 2 rat lungs from one of the 
experimental groups, yielding a total of 3 pooled samples per group or 12 samples 
in total. Each pooled sample was analyzed in two-fold either being labeled with 
Cyanine 3 or Cyanine 5 in a semi-randomized cross-over design, where in 2 cases 
samples served as their own controls on one microarray slide to determine variation 
due to dye type, while the other samples were hybridized in a random way. 
Microarrays
Microarrays contained 26,962 oligonucleotides available in the Operon-Rat Array 
list (V3.0, available at http://microarray.uc.edu/) representing genes from a diverse 
range of functionalities. Positive and negative controls were also represented on the 
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arrays. Microarrays were obtained from the Genomics and Microarray laboratory 
(University of Cincinatti, Cincinatti, OH, USA). 
Probe construction
For each RNA sample, first strand amino-modified cDNA was synthesized by Lin-
Amp oligo dT primed reverse transcription of 2 ug RNA using Superscript II reverse 
transcriptase (Invitrogen, Carlsbad, CA, USA). Doublestranded cDNA was synthe-
sized by E. Coli DNA polymerase I (Invitrogen) and purified with a PCR purification 
kit (Qiagen). Subsequent in vitro transcription of the cDNA was performed em-
ploying the T7 Megascript kit (Ambion, Austin, TX, USA). The reaction was stopped 
after 16 hours at 37°C by purification of the amplified RNA (Qiagen, RNeasy mini). 
Five µg of the amplified aminoallyl-RNA was fluorescently labeled with Cyanine 
3 or Cyanine 5 fluorophores (Amersham Biosciences, Buckinghamshire, UK). La-
beled RNA was purified using Microcon YM-30 columns (Millipore, Billerica, MA, 
USA). Hybridization was performed after mixing the labeled RNA samples from 
the appropriate samples with 15 μg poly-dA DNA (Qiagen). Hybridizations were 
performed under liftersslips (Erie Scientific, Portsmouth, NH, USA) within hybrid-
ization chambers (Telechem, Sunnyvale, CA, USA). After hybridization the slides 
were washed, dried and scanned at 10 µm resolution in a GMS 428 laser scanner 
(Affymetrix, Santa Clara, CA, USA). Image intensity data for each spot were extracted 
by ImaGene version 5.6 software (BioDiscovery, El Segundo, CA, USA).
Microarray analysis
To account for dye bias, signal data were log-transformed and normalized by in-
tensity-dependent regression (Lowess). After filtering of empty spots, control spots, 
spots with high between-pixel-intensity variability and spots designated as bad by 
eye, a scatterplot for the median signal intensity of both fluorescent labels was con-
structed. Moreover, a multivariate permutation test was applied to account for a false 
discovery rate of maximal 10% in the set of significantly differentially expressed 
genes. Genes that showed a significant (p < 0.005) change, taking into account both 
dyes and 3 samples per group, were considered candidates. Analyses were performed 
using BRB ArrayTools developed by Dr. Richard Simon and Amy Peng Lam (http://
linus.nci.nih.gov/BRB-ArrayTools.html).
Clustering of the significantly regulated genes was performed on the basis of their 
differences as they appeared in different pairwise comparisons, according to a meth-
od described by Buermans et al 17. If the expression level of a gene was significantly 
different between the control rats and the monocrotaline-treated rats, it was denoted 
with a ‘1’, and if there was no difference observed as a ‘0’. This was also done for 
monocrotaline versus MC + AV and for MC + AV versus control rats. With three pair 
wise comparisons, 7 combinations are possible. A gene with no significant differ-
ence between controls and monocrotaline-treated rats (0), a significant difference 
between monocrotaline-treated rats and MC + AV rats (1) and a significant differ-
ence between MC + AV rats and control rats (1) would then be assigned to cluster 
0-1-1. In the remainder of the article, these clusters will be addressed as cluster 
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I 0 1 1 9 5/4 5
II 1 1 0 18 16/2 1
III 0 0 1 69 18/51 24
IV 1 0 0 75 67/8 4
V 0 1 0 38 22/16 6
VI 1 1 1 1 1/0 1
VII 1 0 1 15 13/2 6
Total 225 Total 142/83 Total 47




F 5’- CTGACCGTGAGCCAGATCAT -3’
R 5’- GTGGACGTTGTCACCTGTGT -3’
IgE-Fc receptor F 5’- GTGAGTGCCACCATTCAAGA -3’
R 5’- TGGTAGCTGCCACTGTCATT -3’
 ATF3 F 5’- AACATCCAGGCCAGGTCTCT -3’
R 5’- GGATGGCGAATCTCAGCTCT -3’
Il-9 receptor F 5’- GGAGATGTCTCCGAGTTCAG -3’
R 5’- CGATGTCGTCTCATCAGTGT -3’
PreproEndothelin-1 F 5’- TTGCTCCTGCTCCTCCTTGA -3’
R 5’- AGCACACTGGCATCTGTTCC -3’
Wnt 5a F 5’- ATTGGAGAAGGCGCGAAGAC -3’
R 5’- ATTCCTTGGCGAAGCGGTAG -3’
Wnt inhibitory factor F 5’- ACTCCTGGCTTCTGCATCTG -3’
R 5’- GGCACTTGCTGAGTTCACAC-3’
Carboxypeptidase Z F 5’- CCTGCCACCTACCTTCATTC -3’
R 5’- ACCTCAGGCTCCATCAGTTC -3’
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I-VII (table 1). Note that in this method, the direction of change is not taken into 
account. 
Real time PCR analysis
Gene specific PCR primers were designed with Clone Manager v.5 to generate am-
plification products with a length of 75-250 bp spanning at least one exon-exon 
junction. Primers were purchased from Biolegio (Nijmegen, The Netherlands). 
Primer pairs were checked for a linear response and for nonspecific products with 
dissociation curves and agarose gel electrophoresis after specific enzymatic diges-
tion. Primer sequences for the different genes are provided in table 2. Changes in 
expression of mentioned genes were confirmed with real time two-step quantitative 
RT-PCR. First, 1 µg RNA was reversely transcribed into cDNA in a 20 µl reaction vol-
ume. Then quantification was performed with SYBR Green PCR reagents (Molecular 
Probes, Leiden, The Netherlands) in an ABI PRISM 5700 Sequence Detection System 
(Applied Biosystems, Nieuwerkerk, The Netherlands), as previously described 18. 
The PCR profile consisted of 5 min at 95°C, followed by 40 cycles with heating to 
95°C for 15 sec and cooling to 60°C for 1 min. 
Pulmonary histopathology
Heart and lungs were weighed and fixed in 3.6% formalin. Pulmonary sections (5 
µm thickness) were stained with resorcin-fuchsin elastin stain for morphometric 
analysis of vascular dimensions according to a previously described protocol 14. In 
lung sections, 40 randomly chosen vessels (10 in each left lung quadrant) with a 
diameter less than 50 micrometer (intra-acinar vessels) were assessed at 200 and 
400 times magnification using an image analysis system (CZ KS400, Imaging As-
sociates, Bicester, UK) 14.
Data from the gene array revealed elevated mast cell marker genes. Therefore, the 
amount of mast cells in the pulmonary tissue of the rats was determined. 
To localize and quantify mast cells in the lungs, toluidin blue stained lung sections 
were counted for their presence. One section of each rat lung was counted. The 
lungs were divided into four structural categories: 1) parenchyma, 2) peribron-
chial, 3) small artery (diameter < 50 micrometer), 4) large artery (diameter > 50 
micrometer). Per section mast cells in five views per category were counted with a 
magnification of 400 times.   
Statistical analysis
Data are presented as mean ± standard error of the mean (SEM). Group differences 
were analyzed using one-way ANOVA testing with Fisher’s protected LSD post-hoc 
testing. Correlation analysis was performed with Pearson’s correlation test. Alpha 
































































































Figure 1. Hemodynamic and 
(histo)pathological characteristics 
of the rats. 
A) Mean pulmonary arterial pressure 
B) Right ventricular hyper-
trophy (RV/(LV + IVS))
C)Intra-acinar vascular occlusion
* = p < 0.05 vs. CON, † = 
p < 0.05 vs. MC + AV.
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Monocrotaline treatment and the creation of an abdominal aortocaval shunt induced 
pulmonary arterial hypertension as described previously 14. Briefly, mean pulmonary 
arterial pressure was increased in the MC and MC + AV rats, and decreased in the 
ILO-group (figure 1A). Right ventricular hypertrophy, presented as right ventricular 
to left ventricular plus septal weight ratio, was present in both the MC and the MC 
+ AV group, and was not altered by treatment (figure 1B). 
All three experimental groups showed increased pulmonary vascular musculariza-
tion as compared with CON (percentage non-muscularized vessels 94 ± 3% in CON, 
63 ± 10% in MC, 74 ± 4% in MC + AV and 60 ± 4% in the ILO group, all p < 0.05 
vs. CON). The same was true for luminal occlusion due to neo-intima formation 
(figure 1C). Moreover, in all three experimental groups, body weights decreased 
(body weight 404 ± 10 g in CON, 359 ± 8 in MC, 343 ± 10 in MC + AV and 352 
± 8 in ILO, all p < 0.01 vs. CON).
Microarray analysis
9559 Of the 22012 genes (43%) passed the criteria for further analysis. Of these 
genes, 387 showed significant changes in the analysis. 
Classifation in clusters
Seven different clusters were formed based on the difference in expression profiles 
between the experimental groups (table 1). Changes in the different clusters are 
presented in graphs in figure 2. 
Cluster I contains 9 genes that were altered only by increased pulmonary blood 
flow. They were not influenced by monocrotaline treatment, but were altered in the 
MC + AV group both compared to CON rats and compared to MC rats. Five of these 
genes were also influenced by iloprost therapy. Two genes from this cluster warrant 
further discussion. Both are transcription factors. Activating transcription factor 3 
(ATF3) is a gene which is linked to stress-induced apoptosis 19. It is upregulated in 
the combination model, and downregulated in the iloprost treated rats compared 
to the pulmonary hypertensive group. Early growth response protein 1 (Egr-1), a 
zinc finger transcription factor, is also upregulated in the MC + AV group, and again 
downregulated in the iloprost group. Egr-1 has a role in atherosclerosis, neointima 
formation and angiogenesis 20. 
In contrast to cluster I, cluster II contains genes that were altered only by monocro-
taline, without an effect of the aortocaval shunt. This cluster contains 18 genes, of 
which only 1 was also affected by therapy. Seven genes play a role in inflammation. 
Immunoglobulin J chain precursor isoform 2, IgE-Fc receptor high affinity I alpha 
polypeptide, complement component 1, heme oxygenase 1 and the immunoglobu-
lin 4G6 heavy chain variable region were all uniformly upregulated by monocro-
taline. Moreover, two mast cell markers, chymase 1 and tryptase beta 1 were found 

































































































MC       MC + A             ILO
MC       MC + AV  ILO
MC        MC + AV   ILO
MC        MC + AV ILO
MC         MC + AV  ILO
MC        MC + AV  ILO
Figure 2. Gene expression plots for the 7 
separate clusters. Y-axis: log2 gene expres-
sion ratios of the 4 groups. The expression 
in the CON group is set to zero. * = signifi-
cant vs. CON group, † = significant vs. MC 
group, ‡ = significant vs. MC + AV group. 
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15, from the BMP/GDF-family, and the potassium channel Kcnk1 were also in-
creased in the monocrotaline-treated rats. 
Cluster III contains genes that are influenced by pulmonary blood flow, while in 
the MC + AV group there are no differences in expression of these genes compared 
to the CON group, suggesting a partially counteracting effect of monocrotaline ad-
ministration. This cluster contains 69 genes, of which the majority was downregu-
lated. Thirty-five percent of these genes (n = 24) were also influenced by iloprost 
treatment, mostly in the opposite direction of the effect of the shunt. The negative 
regulator of programmed cell death ‘defender against cell death 1’ (Dad1) and the 
pro-proliferative platelet-derived growth factor receptor-like (Pdgfrl), pleiotrophin 
(Ptn) and the heparin-binding growth-associated molecule were all downregulated 
as effect of the shunt. The 5-hydroxytryptamine 1B receptor (Htr1b) and the potas-
sium voltage-gated channel from the shaker-related subfamily were both upregu-
lated as effect of the shunt. Interestingly, endothelin-1, an important mediator of 
pulmonary arterial hypertension in patients, was also upregulated as effect of the 
shunt. However, this change was not significant compared to control rats. 
Cluster IV contains genes that are influenced by monocrotaline, while the increase 
of pulmonary blood flow renders these changes non-significant in the MC + AV 
group, suggesting a partially counteracting effect. This cluster contains a total of 
75 genes, most of which increase under the influence of monocrotaline. Only 4 
of these genes were also influenced by iloprost treatment. A disintegrin-like and 
metalloprotease with thrombospondin type 1, fibronectin 1 (Fn1) and connective 
tissue growth factor, that all play a role in matrixremodeling, were increased, as were 
coagulation factor 2, the interleukin 9 receptor and annexin A5, which binds to 
phosphatidylserine, one of the “eat me” signals on the surface of a cell in apoptosis. 
Finally, the expression of the potassium inwardly-rectifying channel Kcnj8 was also 
increased. 
The regulation of genes in cluster V is complex, since these 38 genes are solely 
altered in the MC + AV group compared to the CON group. Thus, they need both 
stressors to be either activated or inactivated. Six of these genes were also influenced 
by treatment with iloprost. Five of these genes were related to inflammation, and 
all of them were increased in the model. Several genes that can be related to cel-
lular proliferation were also altered in this cluster. Frizzled-related protein (Frzb), a 
protein from the Wnt-signaling cascade, was increased. The fibroblast growth factor 
intracellular binding protein (Fibp), with a role in matrix remodeling, was also 
increased, while the neuropeptide Y receptor Y2 (Npy2r), that plays a role in the 
migration, proliferation and tube formation of endothelial cells was decreased. The 
oxidized low density lipoprotein receptor 1 (Oldlr1), that mediates the recognition, 
internalization and degradation of the atherosclerotic marker oxidized low density 
lipoprotein (ox-LDL) by vascular endothelial cells was increased. The 5-hydroxy-
tryptamine receptor type 2B (Htr2b), however, was decreased in rats that received 
the combination of monocrotaline and a shunt.
Cluster VI was designed to contain genes that were altered by monocrotaline, by 
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Gene array           PCR Gene array           PCR 
Figure 3. Comparison of gene array and PCR-data. 
A) Tryptase, B) IgE-Fc receptor, C) ATF3, D Il-9 receptor, E) Endothe-
lin-1, F) Wnt 5a, G) Wnt inhibitory factor, H) Carboxypeptidase Z.
* = p < 0.05 vs. CON, † = p < 0.05 vs. MC, ‡ = p < 0.05 vs MC + AV. 
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After analysis of the data, it revealed 1 gene that changed under all circumstances, 
including therapy. This sequence was similar to DEAD (Asp-Glu-Ala-Asp) box poly-
peptide 41, one of the helicases which play a role in RNA metabolism.
Cluster VII represents the genes that are changed by monocrotaline, but counter 
regulated by the addition of increased blood flow. They are changed both in MC rats 
compared to CON rats and in the MC + AV group compared to the MC rats, without 
difference between the MC + AV group and CON rats. This cluster contained 15 
genes. Carboxypeptidase Z, an enzyme which contains a Cys-rich domain that has 
homology to Wnt-binding proteins, and caspase 6 were upregulated in the mono-
crotaline model, and downregulated to control levels after addition of the shunt. Six 
of these 15 genes were also influenced by iloprost treatment. All 6 were increased 
after iloprost treatment compared to the MC + AV group. 
In general, a total of 209 genes were altered due to iloprost treatment. Forty-seven 
of these genes were also regulated by the model (cluster 1 to 7). Among the genes 
regulated by iloprost treatment were several that are involved in Wnt-signaling, 
namely Wnt-inhibitory factor 1, Wnt5a, catenin alfa 1, secreted frizzled related pro-
tein (sfrp2) and frizzled homolog 5. 
PCR confirmation
The expression of eight genes that caught our interest because of their possible im-








































Figure 4. Mast cell count in 
the lungs of the different rat 
groups. * = p < 0.05 vs. CON, 
‡ = p < 0.05 vs. MC + AV. 
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In all eight genes tested (100%; figure 3), changes were in a similar direction as 
predicted from the microarray data. In 3 of the 8 genes, PCR confirmation led to the 
finding of additional significant comparisons, while in two cases, PCR data did not 
result in significant differences but showed a trend in a similar direction. In the three 
remaining genes, the significance of the changes was identical. 
Mast cell count
We wanted to confirm the gene array and PCR findings of increased expression of 
the mast cell markers chymase 1 and tryptase beta 1. Therefore, the actual presence 
of mast cells was verified by counting their numbers in pulmonary sections.
The number of mast cells increased around the vessels and in the parenchyma in 
the monocrotaline-treated rats (figure 4). In rats from the MC + AV group, similar 
changes were found. Iloprost treatment decreased the number of mast cells both in 
the perivascular area and in the parenchyma. 
 Discussion
In this model for PAH in rats, we identified several pathways important in the de-
velopment of monocrotaline-induced pulmonary hypertension, as well as in the 
additional effect of increased pulmonary blood flow. Further, we addressed those 
genes that were affected by iloprost therapy, a previously proven effective therapy 
in humans. Monocrotaline-induced pulmonary hypertension was associated with 
alterations in Wnt-signaling and with mast cell proliferation. Increased pulmonary 
blood flow specifically leads to increased expression of ATF3 and Egr-1. Further-
more, treatment with iloprost affected both genes from the Wnt-signaling pathway 
as mast cell proliferation. 
In order to obtain statistically important results, the array was performed in a cross-
over design, which provides outcomes according to the MIAME agreements 16. To be 
absolutely sure of the validity of our data, we verified some key genes by real-time 
PCR. Indeed, all genes were regulated in similar ways when PCR and gene array data 
were compared. 
Our array analysis yielded several genes that were already known to be involved in 
the pathophysiology from patient studies. Examples are the upregulation of endo-
thelin-1 after induction of increased pulmonary blood flow 21. Changes in potassium 
channel expression, serotonin signaling and in pro-inflammatory and pro-apoptotic 
activation have also been described in patients 22. In a gene array in patients with 
pulmonary hypertension, similar, although not identical patterns of altered gene 
expression were discovered. For example, alterations in a DEAD box polypeptide and 
in several types of potassium channels 23 were described before. However, this gene 
array also yielded several pathways that have not been previously connected with the 
development of PAH.
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One of the new factors emerging from our array is activating transcription factor 
3 (ATF3). ATF3 is part of the ATF/CREB family of transcription factors. It is a gene 
that is induced in stress conditions, for example in myocardial ischemia 19, which 
in its homodimeric form acts as a transcription repressor, while it can act as a tran-
scription activator in a heterodimeric configuration with c-Jun. Although it is not 
exactly clear what the inducers, target genes and responses of ATF3 are, its activa-
tion does seem to contribute to organ dysfunction, as was illustrated by liver and 
cardiac malfunctioning after induction 24;25. In our model, ATF3 is highly induced 
by increased pulmonary blood flow (figure 3C), suggesting a specific role in flow-
associated PAH.
Another gene specifically induced by increased blood flow is early growth response 
protein 1 (Egr-1). Egr-1 is a master regulator that controls the expression of a variety 
of genes. It plays a role in several cardiovascular processes such as atherosclerosis, 
intimal thickening and angiogenesis 26. Its activation is regulated by many different 
stimuli, amongst which mechanical injury 27, angiotensin II 28 and shear stress 29. 
Under hypoxic conditions, it has been described that Egr-1 expression is increased 
in pulmonary adventitial fibroblasts 30. Interestingly, Egr-1 apparently is involved 
in the Il-13 and tumor necrosis factor production by mast cells 31. It is conceivable 
that both ATF3 as well as Egr-1 contribute considerably to the pathogenesis of PAH. 
Therefore, research on animals with gain of function mutations, as described for 
ATF3 in the heart 24 might add to our expanding knowledge on the disease. 
Wnt-signaling
The Wnt pathway deserves further attention as components of this pathway are in-
duced in flow-associated PAH and reduced by iloprost therapy (figure 3 F-H). The 
Wnt family controls a variety of processes including proliferation and migration 32 
and is important in pulmonary development, but also in pulmonary inflammation 
and oncology. Signaling is complex and occurs via at least three signaling pathways. 
Signaling is further modulated by several regulatory molecules, of which Wnt5a is 
an example. Target genes of the Wnt pathways include matrix metalloproteinases, 
cyclo-oxygenase-2 and the VEGF-receptor. All of these substances have their own 
contribution to the pathogenesis of PAH. For example, the WNT5a-null mice display 
increased expression of BMP4 33, a gene of which the receptor has been shown to be 
involved in patients with PAH 34. 
In this study, we found several components of the Wnt system to be regulated. Frizz-
led related protein B (FrzB), an inhibitor of Wnt-signaling, and carboxypeptidase 
Z were increased in the MC + AV group and in the MC-group respectively. Car-
boxypeptidase Z was downregulated to control levels after addition of the shunt. 
This enzyme also recently has been discovered to play a stimulating role in Wnt 
signaling 35. Additionally, Wnt-inhibitory factor 1, Wnt5a, catenin alfa 1, secreted 
frizzled related protein 2 (sfrp2) and frizzled homolog 5 were all upregulated after 
treatment with iloprost. Sofar, an effect of iloprost therapy on Wnt-signaling has 
not been described in literature. The net effect of iloprost intervention on the Wnt 
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pathway remains difficult to predict, because although Wnt5a is an activator of one 
of the signaling pathways of Wnt and frizzled 5 is its receptor, the frizzled related 
proteins and the Wnt-inhibitory factor antagonize Wnt-signaling 36. Since activation 
of Wnt-signaling leads to pulmonary inflammation and the induction of tumor for-
mation, it could be hypothesized that in a similar way activation of Wnt-signaling 
contributes to pulmonary vascular remodeling in PAH and that iloprost interferes 
in this process 32.
Mast cell involvement
Genes that were selectively regulated by monocrotaline were mainly associated with 
inflammation (heme oxygenase 1), and more specifically, with the presence of mast 
cells (IgE-Fc receptor, tryptase beta 1, chymase 1). This confirms that inflammation 
is important in the vascular remodeling that occurs as a consequence of monocro-
taline administration. To address the question whether mast cells contribute to the 
pathofysiological process, a toluidine blue staining was performed and the amount 
of mast cells was counted. 
An increased number of mast cells was present in the lungs of the monocrotaline- 
treated rats. It had been previously shown by Vaszar et al that mast cells and their 
related protein expression levels started to rise significantly 21 days after moncrota-
line injection, and not earlier 37. Hence, the increased mast cell count in our model 
probably reflects the pulmonary vascular remodeling, rather than inflammation due 
to monocrotaline itself. Increased mast cell counts are also present in patients with 
PAH due to a CHD 38.
The addition of a shunt to the monocrotaline rat model did not affect the amount of 
mast cells and mast cell markers in the lungs. However, a trial in patients showed that 
also patients with a sole increase in pulmonary blood flow due to an atrial septal de-
fect 38 display increased numbers of mast cells. We probably do not see an additional 
effect of the shunt because of the strong pro-inflammatory effects of monocrotaline. 
A longer trial without monocrotaline might show that there also is a flow inducible 
effect on the presence of mast cells in rats.
The involvement of mast cells in the development of PAH has received little at-
tention. They are known as potent angiogenic stimulators 39;40 and play a role in 
angiotensin II mediated vasoconstriction 41. Literature states that activated mast cells 
can contribute to vessel remodeling using specific serine proteases from their gran-
ules  42;43. Furthermore, chymase has been connected to the conversion of angioten-
sin I to the vasoconstrictor angiotensin II 41 and blockade of angiotensin II prevents 
the development of arteriolar hypertrophy. Together, this suggests that the excessive 
mast cells present in arteries of PAH patients and models are enhancing the develop-
ment of the disease. 
Treatment with iloprost led to a decrease in the number of mast cells, although it did 
not appear to alter the presence of mast cell markers on PCR. This may be due to the 
fact that iloprost is known to inhibit mast cell degranulation, through calcium influx 
and elevation of cAMP levels 44. Possibly, the introduction of iloprost inhibits mast 
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cells to secrete histamine, secondary also inhibiting chymase and tryptase secretion. 
Chymase and tryptase may be accumulating in the mast cell under influence of he-
modynamic stress, but the inability to release them possibly prevents the prolifera-
tion of additional mast cells. 
Effects of therapy
Evaluating the effect of iloprost in this model, it appeared that genes that were most-
ly affected by iloprost treatment were those genes that changed specifically after the 
addition of increased pulmonary blood flow. Less often, ilopost was able to antago-
nize the effects of monocrotaline. Interestingly, iloprost seems therefore particularly 
effective in antagonizing the effects of increased flow.
In conclusion, in this rat model of flow-associated PAH, we used a cross-over de-
signed microarray to identify novel pathways in the pathogenesis of PAH and in the 
therapeutic effects of iloprost. We showed that both monocrotaline and increased 
pulmonary blood flow each contribute to specific changes in pulmonary gene ex-
pression. Treatment with iloprost partly reverses these changes. New pathobiological 
pathways that emerged from this analysis were ATF3 and Egr-1, both induced by in-
creased pulmonary blood flow, and Wnt-signaling and mast cell proliferation, both 
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